Recently, the accelerated development of 3D printing technology has opened up the possibility of its application in many industries, including the pharmaceutical industry. 3D printing technology has a major contribution to the modernization of the pharmaceutical industry due to its many advantages, such as the simplicity of model design and the ability to print complex forms. Acceptance of the 3D printing in the pharmaceutical industry is also proven by FDA approval of the first 3D printed tablet. In this research, two capsule models were designed and 3D printed. Super-H and Limenka models are designed for the purpose of controlled release of the active substance. Capsules are printed from poly(vinyl-alcohol), a biodegradable pharmaceutically acceptable polymer. As a model drug in this research dronedarone hydrochloride, a medicine for cardiac arrhythmia was used. The study investigates the release of the dye powder from the capsules, the optical analysis of the quality of Super-H membrane and the release of dronedarone hydrochloride in phosphate buffer pH 4.5, a FeSSIF solution that simulates fed state intestinal fluid and FaSSIF solution that simulates the fasted state intestinal fluid. The results show that the modification of the membrane thicknesses of the Super-H capsule cover has a significant effect on the release rate. Controlled release can be achieved with the combination of caps. The model Limenka achieves controlled extended release. Capsule design allows control of drug release by modifying the thickness of the wall and adjusting the geometry of capsules.